Neos Therapeutics (NASDAQ:NEOS) posted its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.02, MarketWatch Earnings reports.

Neos Therapeutics stock opened at $2.59 on Friday. The firm has a market capitalization of $65.89 million, a PE ratio of -0.97 and a beta of 0.96. Neos Therapeutics has a 1-year low of $1.40 and a 1-year high of $9.24.

An institutional investor recently raised its position in Neos Therapeutics stock. Geode Capital Management LLC lifted its holdings in Neos Therapeutics Inc (NASDAQ:NEOS) by 41.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 367,496 shares of the company’s stock after purchasing an additional 107,627 shares during the quarter. Geode Capital Management LLC owned about 1.24% of Neos Therapeutics worth $606,000 as of its most recent SEC filing. Institutional investors and hedge funds own 85.15% of the company’s stock.

A number of analysts have recently weighed in on the company. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Wednesday, January 16th. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, December 26th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.69.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: What are the benefits of a balanced fund?

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with's FREE daily email newsletter.